The broker said the company's full-cap bitcoin strategy is maturing, as preferred equity drives accretion and a new S&P credit rating expands its investor base.
The nanocap biotech firm is pivoting into digital assets with a $540 million raise to build a canton coin–based treasury, backed by DRW and Liberty City Ventures.